| Value | ₹1,158 Cr |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹733.15
- Market cap
- ₹11,539 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.6×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Other results update announcements
All →Balmer Lawrie & Company Results Update
Balmer Lawrie reported Q2 FY27 net total income of Rs. 818.04 crore, up 26.34%, and PAT of Rs. 67.66 crore, up 39.56%. The press release covers results for the quarter ended 30 September 2026.
Puravankara Results Update
Puravankara's Q2FY27 revenue rose 59% to ₹1,051 crore and PAT reached ₹82 crore. The press release also covers sales, handovers and new land and project additions.
Viviana Power Tech Results Update
Viviana Power Tech reported H1 FY27 standalone revenue of ₹18,907 lakhs, up 173% YoY, with PAT of ₹1,861 lakhs. The press release also announces proposed disinvestment of its stakes in two subsidiaries.
- Order book
- ₹1,800 Cr
ideaForge Technology Results Update
ideaForge reported Q2 FY27 revenue of ₹91.3 crore and PAT of ₹6.5 crore, turning profitable. H1 revenue reached a record ₹159.9 crore.
S H Kelkar & Company Results Update
S H Kelkar and Company released its Q2 and H1 FY27 results press release and investor presentation. H1 revenue rose 14.5% and EBITDA margin reached 13.0%.
Kody Technolab Results Update
Kody Technolab shared its H1FY27 shareholder letter with consolidated headline results and operating highlights. The letter reports revenue, EBITDA and PAT growth alongside robot deployment figures.